Nicox to re-focus naproxcinod on Duchenne muscular dystrophy
14 Février 2014 - 7:34AM
Nicox S.A. (NYSE Euronext Paris:
COX) today announced its decision to re-focus naproxcinod
development efforts. Nicox has granted an undisclosed financial
partner the right to enter into a period of exclusive evaluation to
assess the potential development of naproxcinod and of next
generation nitric oxide (NO)- donors outside the ophthalmology
area. The evaluation will be entirely funded by this partner and
will be focused initially on Duchenne muscular dystrophy (DMD).
Nicox has granted the undisclosed partner the exclusive right,
should the results of the evaluation be satisfactory to the
partner, to invest at the end of the evaluation period in
naproxcinod and next generation NO-donors outside ophthalmology
through an independent structure. Nicox will not pursue any other
development activities or discussions with third parties related to
naproxcinod.
Naproxcinod is a CINOD (Cyclooxygenase-Inhibiting Nitric
Oxide-Donating) anti-inflammatory candidate. In October 2013, the
European Commission granted Orphan Drug Designation for naproxcinod
for the treatment of DMD. DMD is the most common and serious form
of muscular dystrophy, a group of inherited diseases that cause
muscle weakness and muscle loss. Promising preclinical results
obtained with naproxcinod in models of muscular dystrophy were
presented at the Muscular Dystrophy Association Scientific
Conference in Washington, DC, in April 2013, and at the
International Congress of the World Muscle Society in Asilomar, CA
in October 2013, and have been published in Human Molecular
Genetics in early 20141.
...................................
Reference
1 Long-term treatment with naproxcinod significantly improves
skeletal and cardiac disease phenotype in the mdx mouse model of
dystrophy, Uaesoontrachoon K, Quinn JL, Tatem KS, Van der Meulen
JH, Yu Q, Phadke A, Miller BK, Gordish-Dressman H, Ongini E,
Miglietta D, Nagaraju K. Hum Mol Genet. 2014, Early online
publication Jan 23, 2014.
...................................
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is
an emerging international company focused on the ophthalmic market.
With a heritage of innovative R&D, business development and
commercial expertise, the Nicox team is building a diversified
portfolio of therapies and diagnostic tools that can help people to
enhance their sight. The Company's commercial portfolio and
near-term pipeline already include several innovative diagnostic
tests intended for eye care professionals, as well as a range of
eye care products. Nicox's key proprietary asset in ophthalmology
is latanoprostene bunod, a novel compound based on Nicox's
proprietary nitric oxide (NO)-donating R&D platform, currently
in Phase 3 clinical development in collaboration with Bausch + Lomb
for the potential treatment of glaucoma and ocular hypertension.
Further NO-donors are under development, notably through
partners.
Nicox is headquartered in France, with research
capabilities in Italy, a growing commercial infrastructure in North
America and in the major European markets and an expanding
international presence through partners. Nicox S.A. is listed on
Euronext Paris (Compartment B: Mid Caps). For more information on
Nicox or its products please visit www.nicox.com.
...................................
This press
release contains
certain forward-looking
statements. Although
the Company
believes its
expectations are
based on
reasonable assumptions,
these forward-looking
statements are
subject to
numerous risks
and uncertainties,
which could
cause actual
results to differ
materially from
those anticipated
in the
forward-looking statements.
Risks factors
which are likely
to have a
material effect
on Nicox's
business are
presented in the
4th chapter of
the « Document
de référence,
rapport financier annuel
et rapport de
gestion 2012 »
filed with the
French Autorité
des Marchés
Financiers (AMF)
on March 22,
2013 and
available on
Nicox's website
(www.nicox.com) and
on the AMF's
website (www.amf-france.org).
...................................
|
Contacts |
|
|
Nicox |
Gavin Spencer |
Executive Vice
President Corporate
Development |
| |
Tel +33
(0)4 97 24 53 00 | communications@nicox.com |
|
Media Relations |
|
|
United Kingdom |
Jonathan Birt |
| |
M +44 7860
361 746 | jonathan.birt@ymail.com |
|
France |
Caroline Courme | Communication
Manager Tel +33 (0)4 97 24 53 43 | courme@nicox.com |
Nicox S.A. Drakkar 2 | Bât D | 2405 route des Dolines | CS 10313
| Sophia Antipolis | 06560 Valbonne | France T: +33 (0)4 97 24 53
00 | F: +33 (0)4 97 24 53 99 www.nicox.com
Nicox to re-focus naproxcinod on Duchenne muscular dystrophy
http://hugin.info/143509/R/1761922/596692.pdf
HUG#1761922
Cox Communications (NYSE:COX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Cox Communications (NYSE:COX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
